| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S11936-016-0486-2 |
| P8608 | Fatcat ID | release_yznysdpddjgjdp4oxzqz5kjape |
| P698 | PubMed publication ID | 27620638 |
| P2093 | author name string | Joshua W Knowles | |
| Ashish Sarraju | |||
| Justin Parizo | |||
| P2860 | cites work | The PCSK9 decade | Q24615397 |
| PCSK9 LNA antisense oligonucleotides induce sustained reduction of LDL cholesterol in nonhuman primates | Q24633470 | ||
| Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study | Q24645376 | ||
| Monogenic hypercholesterolemia: new insights in pathogenesis and treatment | Q24672834 | ||
| Risk of fatal coronary heart disease in familial hypercholesterolaemia. Scientific Steering Committee on behalf of the Simon Broome Register Group | Q24675141 | ||
| Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society | Q27024882 | ||
| ODYSSEY MONO: effect of alirocumab 75 mg subcutaneously every 2 weeks as monotherapy versus ezetimibe over 24 weeks | Q39052365 | ||
| Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial | Q39091664 | ||
| Attainment of LDL-Cholesterol Treatment Goals in Patients With Familial Hypercholesterolemia: 5-Year SAFEHEART Registry Follow-Up. | Q39910939 | ||
| Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients: The ODYSSEY OPTIONS II randomized trial | Q40241401 | ||
| Monogenic primary hypercholesterolaemia in South Africa | Q40519357 | ||
| Results of bococizumab, a monoclonal antibody against proprotein convertase subtilisin/kexin type 9, from a randomized, placebo-controlled, dose-ranging study in statin-treated subjects with hypercholesterolemia | Q41200136 | ||
| Homozygous autosomal dominant hypercholesterolaemia in the Netherlands: prevalence, genotype-phenotype relationship, and clinical outcome | Q42646027 | ||
| Anacetrapib as lipid-modifying therapy in patients with heterozygous familial hypercholesterolaemia (REALIZE): a randomised, double-blind, placebo-controlled, phase 3 study | Q42702371 | ||
| Safety of Anacetrapib in Patients with or at High Risk for Coronary Heart Disease | Q42807626 | ||
| Effect of mipomersen, an apolipoprotein B synthesis inhibitor, on low-density lipoprotein cholesterol in patients with familial hypercholesterolemia | Q43069511 | ||
| Efficacy and safety of mipomersen, an antisense inhibitor of apolipoprotein B, in hypercholesterolemic subjects receiving stable statin therapy | Q43105910 | ||
| Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial | Q43130496 | ||
| Evaluation of cholesterol lowering treatment of patients with familial hypercholesterolemia: a large cross-sectional study in The Netherlands. | Q43264146 | ||
| Mipomersen, an apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: a randomized, double-blind, placebo-controlled trial | Q44963629 | ||
| Effect of the proprotein convertase subtilisin/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia | Q45831677 | ||
| PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial | Q46215056 | ||
| Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab | Q46383780 | ||
| Reduction in mortality in subjects with homozygous familial hypercholesterolemia associated with advances in lipid-lowering therapy | Q46408437 | ||
| A 52-week placebo-controlled trial of evolocumab in hyperlipidemia | Q46576710 | ||
| Update and analysis of the University College London low density lipoprotein receptor familial hypercholesterolemia database | Q46715028 | ||
| Coronary artery disease in 116 kindred with familial type II hyperlipoproteinemia | Q47889721 | ||
| Familial hypercholesterolemia in the danish general population: prevalence, coronary artery disease, and cholesterol-lowering medication. | Q50557022 | ||
| Severe hypertriglyceridemia with pancreatitis: thirteen years' treatment with lomitapide. | Q51329619 | ||
| Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B. | Q55042558 | ||
| Contribution of receptor negative versus receptor defective mutations in the LDL-receptor gene to angiographically assessed coronary artery disease among young (25–49 years) versus middle-aged (50–64 years) men | Q57316331 | ||
| Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: The ODYSSEY COMBO I study | Q57635513 | ||
| Sudden Death in a 4-Year-Old Boy: A Near-Complete Occlusion of the Coronary Artery Caused by an Aggressive Low-Density Lipoprotein Receptor Mutation (W556R) in Homozygous Familial Hypercholesterolemia | Q59436465 | ||
| Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial | Q61451343 | ||
| Serum lipids and coronary heart disease in heterozygous familial hypercholesterolemia in the Hokuriku district of Japan | Q67051179 | ||
| Natural history and cardiac manifestations of homozygous familial hypercholesterolaemia | Q68567438 | ||
| Homozygous familial hypercholesterolemia among French Canadians in Québec Province | Q69960600 | ||
| The Lebanese allele at the low density lipoprotein receptor locus. Nonsense mutation produces truncated receptor that is retained in endoplasmic reticulum | Q70157766 | ||
| Relation of cholesterol-year score to severity of calcific atherosclerosis and tissue deposition in homozygous familial hypercholesterolemia | Q71024578 | ||
| Usefulness of electron beam tomography in adolescents and young adults with heterozygous familial hypercholesterolemia | Q77648663 | ||
| Efficacy of apolipoprotein B synthesis inhibition in subjects with mild-to-moderate hyperlipidaemia | Q84142136 | ||
| Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial | Q85678153 | ||
| Normalization of low-density lipoprotein receptor expression in receptor defective homozygous familial hypercholesterolemia by inhibition of PCSK9 with alirocumab | Q86130025 | ||
| Proprotein convertase substilisin/kexin type 9 antagonism reduces low-density lipoprotein cholesterol in statin-treated hypercholesterolemic nonhuman primates | Q27675168 | ||
| Mutations in PCSK9 cause autosomal dominant hypercholesterolemia | Q28202519 | ||
| Mortality in treated heterozygous familial hypercholesterolaemia: implications for clinical management. Scientific Steering Committee on behalf of the Simon Broome Register Group | Q28295362 | ||
| Sequence variations in PCSK9, low LDL, and protection against coronary heart disease | Q29616310 | ||
| Effects of torcetrapib in patients at high risk for coronary events | Q29619609 | ||
| Treatment Gaps in Adults With Heterozygous Familial Hypercholesterolemia in the United States: Data From the CASCADE-FH Registry | Q31063192 | ||
| Longitudinal evaluation and assessment of cardiovascular disease in patients with homozygous familial hypercholesterolemia | Q33386394 | ||
| Diagnostic Yield and Clinical Utility of Sequencing Familial Hypercholesterolemia Genes in Patients With Severe Hypercholesterolemia | Q33605196 | ||
| Lomitapide and mipomersen: two first-in-class drugs for reducing low-density lipoprotein cholesterol in patients with homozygous familial hypercholesterolemia | Q34040047 | ||
| Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. | Q34043472 | ||
| Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society | Q34071937 | ||
| Determination of the role of the human RNase H1 in the pharmacology of DNA-like antisense drugs | Q34298362 | ||
| Effects of dalcetrapib in patients with a recent acute coronary syndrome | Q34309967 | ||
| Efficacy and safety of alirocumab in reducing lipids and cardiovascular events | Q34467233 | ||
| Randomized, placebo-controlled trial of mipomersen in patients with severe hypercholesterolemia receiving maximally tolerated lipid-lowering therapy | Q34477657 | ||
| Microsomal triglyceride transfer protein: a multifunctional protein | Q35109358 | ||
| Long-term efficacy and safety of mipomersen in patients with familial hypercholesterolaemia: 2-year interim results of an open-label extension | Q35132715 | ||
| Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial | Q35603530 | ||
| Current management of severe homozygous hypercholesterolaemias | Q35830954 | ||
| Familial hypercholesterolemia and coronary heart disease: a HuGE association review | Q35867786 | ||
| Alirocumab as Add-On to Atorvastatin Versus Other Lipid Treatment Strategies: ODYSSEY OPTIONS I Randomized Trial. | Q35916476 | ||
| The lipid-lowering effects of lomitapide are unaffected by adjunctive apheresis in patients with homozygous familial hypercholesterolaemia - a post-hoc analysis of a Phase 3, single-arm, open-label trial. | Q36069577 | ||
| Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study | Q36104706 | ||
| ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia | Q36278291 | ||
| Efficacy of statins in familial hypercholesterolaemia: a long term cohort study | Q36973946 | ||
| Metabolic studies in familial hypercholesterolemia. Evidence for a gene-dosage effect in vivo | Q37040813 | ||
| Long-Term Risk of Atherosclerotic Cardiovascular Disease in US Adults With the Familial Hypercholesterolemia Phenotype | Q37066247 | ||
| Familial hypercholesterolemia: epidemiology, Neolithic origins and modern geographic distribution | Q37887013 | ||
| Homozygous familial hypercholesterolemia: current perspectives on diagnosis and treatment | Q37991466 | ||
| Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial. | Q38430399 | ||
| Familial hypercholesterolemia mutations in the Middle Eastern and North African region: a need for a national registry | Q38441332 | ||
| Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: results of a randomized, double-blind, placebo-controlled trial to assess efficacy and safety as add-on therapy in patients with coronary artery dis | Q38462674 | ||
| The Agenda for Familial Hypercholesterolemia: A Scientific Statement From the American Heart Association | Q38618619 | ||
| P433 | issue | 11 | |
| P921 | main subject | hypercholesterolemia | Q762713 |
| P304 | page(s) | 64 | |
| P577 | publication date | 2016-11-01 | |
| P1433 | published in | Current treatment options in cardiovascular medicine | Q27714743 |
| P1476 | title | Novel Therapies for Familial Hypercholesterolemia | |
| P478 | volume | 18 |
Search more.